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Abstract
Major depressive disorder (MDD) affects approximately 17.3 million adults in the United States
each year. For more than 50 years, the serotonin hypothesis of MDD, which hypothesizes that a
deficiency of monoaminergic neurotransmitters results in depression, has been the foundation for
neuropsychological research. However, studies reveal that only an estimated 50% of MDD
patients respond to traditional, biogenic-amine-based antidepressants (ADs), like selective
serotonin reuptake inhibitors (SSRIs). Research has noted that the neuroplasticity hypothesis,
which posits that weakened excitatory synaptic transmission results in depression, offers an
alternative mechanism by which ketamine-like drugs lacking the abuse liability and psychoactive
effects of ketamine are able to induce AD-like effects. This study focuses on establishing the
importance of the neuroplasticity hypothesis of MDD in relation to novel ADs and designing
clinical trials that will help determine the most effective and fastest-acting MDD treatments. A
compilation of studies involving rodent models of depression, MDD patients, and postmortem
hippocampus analyses was examined in order to understand the relationship between longstanding theories and newer hypotheses of how depression manifests in rat and human brains.
Research shows that because ketamine-like drugs, including L-655,708 and (2R,6R)hydroxynorketamine (HNK), modulate α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptor (AMPAR) expression to promote neuroplasticity, the novel compounds induce AD-like
effects within twenty-four hours and strengthen the brain’s cortico-mesolimbic reward pathway
in rodent models of depression. While the monoamine theory and the neuroplasticity theory of
MDD focus on different mechanisms by which ADs reverse stress-induced changes in synaptic
strength and hedonic behavior, the theories overlap to justify the ability of ketamine-like drugs,
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which act as AMPAR potentiators, and biogenic-amine-based ADs to augment each other’s
activity. More clinical trials must be conducted in order to understand if and how the
simultaneous administration of ketamine-like drugs and traditional ADs could result in shorter
latency periods and higher efficacies in MDD therapies. Dual-drug treatments that maximize the
synergism between long-standing and novel ADs may offer a new therapy method that would
alleviate the severe depressive symptoms faced by a large population of treatment-resistant MDD
patients.
Keywords: depression, monoamine, neuroplasticity, SSRIs, ketamine, ketamine-like
drugs

SUBSTANTIALITY OF NEUROPLASTICITY HYPOTHESIS OF MDD

4

The Substantiality of the Neuroplasticity Hypothesis of Major Depressive Disorder:
The Prospective Use of Ketamine-Like Drugs as Antidepressants
Introduction
MDD is a severe neuropsychiatric syndrome that affects approximately 16% of the
world’s population. To relieve the symptoms of the disorder, current pharmacological treatments
target biogenic amine neurotransmitters that affect mood and behavior in the brain. Each
treatment is based on a different hypothesis of MDD proposed by the scientific community. The
most common of such theories is the monoamine hypothesis of depression, which states that a
decrease in the release, synthesis, or receptor expression of monoamine neurotransmitters,
especially serotonin, causes depression. For more than 50 years, researchers have relied upon the
monoamine hypothesis of depression to develop traditional, biogenic-amine-based ADs, like
SSRIs. However, according to Thompson et al. (2015)—who performed a meta-analysis on
current trends in depression research—SSRIs are only effective in approximately 50% of MDD
patients and have a latency period of up to 12 weeks (p. 280).
Due to the fact that only 70% of MDD patients are able to achieve complete remission
with current therapy options, the neuroscience community recently launched itself into the search
for a new hypothesis of MDD and a novel treatment option for MDD patients who are resistant
to traditional ADs. In response to the debate on the cogency of the monoamine theory of MDD,
Thompson et al. proposed a new model of MDD: the neuroplasticity hypothesis or the excitatory
synapse hypothesis of MDD. The hypothesis is based on evidence that chronic stress damages
synaptic strength in areas of the brain—including the nucleus accumbens (NAc), the ventral
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tegmental area, the prefrontal cortex (PFC), the lateral habenula, the amygdala, and the
hippocampus—that are associated with the control of reward behaviors (p. 281-287).
The novel neuroplasticity hypothesis of MDD offers a mechanism by which ketamine is
able to induce rapid and robust AD-like effects in rodent and human models of depression. While
ketamine does relieve depressive symptoms within twenty-four hours of a single administration,
its abuse liability and psychoactive effects limit its clinical viability to treat traditional-ADresistant MDD patients. However, according to Thompson et al., ketamine-like drugs, like L655,708 and (2R,6R)-HNK, act via a similar mechanism as ketamine but lack the harmful side
effects; ketamine-like drugs act as AMPAR potentiators in order to promote excitatory synaptic
transmission in the brain, which induces neuroplasticity. The ability of ketamine-like drugs to
influence both monoaminergic and glutamatergic systems within the brain indicates that there is
an overlap between the monoamine hypothesis of MDD and the neuroplasticity hypothesis of
MDD.
Preliminary research in rats has shown that traditional ADs and ketamine-like drugs may
augment each other’s activity, which suggests that the scientific community can develop new
therapies for traditional-AD-resistant MDD patients by exploiting the synergism between the two
classes of drugs. Because ketamine and ketamine-like drugs—including L-655,708, MRK-016,
(2R,6R)-HNK, LY 451646, and LY 392098—modulate AMPAR expression to promote
neuroplasticity, the novel compounds quickly induce AD-like effects and strengthen the brain’s
cortico-mesolimbic reward pathway. Simultaneous administration of ketamine-like drugs, which
act as AMPAR potentiators, and traditional ADs, like SSRIs, could result in new MDD
treatments with shorter latency periods and higher efficacies for MDD patients who are unable to
achieve symptom relief with ADs that are based on the older, monoamine model of depression.
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Neuroplasticity Hypothesis of Depression
The neuroplasticity theory proposed by Thompson et al. highlights the brain’s ability to
modify the function of its pathways and alter the strength of synaptic connections as a result of
external stimuli such as chronic stress. By increasing cortical activity, the brain forms new neural
connections to reverse the changes caused by chronic stress and MDD. The neuroplasticity
hypothesis is supported by the findings of Duric et al. (2012), who studied the expression of
synapse-related and glutamate-related genes in the hippocampi of MDD patients. Duric et al.
claimed that pre-synaptic and post-synaptic genes involved in cytoskeletal rearrangement and
glutamate receptor subtypes are dysregulated in the dentate gyrus (DG) and the CA1 area of the
hippocampus of depressed individuals (p. 73). The idea that the dysregulation of synapses in the
brain’s reward pathway results in depression is central to the neuroplasticity hypothesis proposed
by Thompson et al. (2015), who asserted that chronic stress changes the strength of
glutamatergic synapses in locations of the brain like the hippocampus.
Duric et al. (2012) argued that long-term changes observed in MDD patients can be
attributed to the downregulation of critical genes, like those that are involved in inducing
synaptic plasticity and remodeling neuronal processes. While Duric et al. claimed that alterations
of serotonin receptors do play a role in anhedonia seen in MDD patients, Thompson et al. (2015)
and Gigliucci et al. (2013)—in a study that investigated the AD-like effects of ketamine in
serotonin-depleted rats—found that in addition to altered monoamine levels in the brain’s reward
pathway, other factors like synaptic strength and brain-derived neurotrophic factor (BDNF)
expression also influence the individuals’ states of mind. Thompson et al. (2015) hypothesized
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that “changes in excitatory synapses in regions” of the brain like the PFC and the hippocampus
“interact with reward circuits in the cortico-mesolimbic system,” which influences the levels of
neurotransmitters—like dopamine, glutamate, and γ-aminobutyric acid (GABA)—and alters
neuronal activity (p. 286-287).
AD-Like Effects of Ketamine and Ketamine-Like Drugs
Research has shown that while chronic administration of traditional ADs like SSRIs can
reverse depressive symptoms in MDD patients, acute administration of ketamine, which is the
focus of the neuroplasticity hypothesis, is able to induce more robust AD-like effects in a shorter
period of time. In the meta-analysis conducted on studies that investigated ketamine and other Nmethyl-D-aspartate receptor (NMDAR) antagonists, Thompson et al. (2015) reported that there
is substantial evidence that ketamine reduces depressive symptoms within one to two hours of
administration and results in behavioral changes that can last for up to two weeks (p. 288).
Thompson et al. further noted that in chronically stressed rodents, administration of ketamine
restores feeding behaviors, food preferences, and social interaction, which is associated with
reward and pleasure (p. 288).
In order to investigate ketamine’s AD capability in a human model of depression,
Murrough et al. (2013) compared the AD effects of an acute administration of the sedative
midazolam and the AD-like effects of an acute administration of ketamine on MDD patients.
Murrough et al. found that the greater the time that had elapsed from the administration of
ketamine or midazolam treatment, the greater the probability that a patient became a
nonresponder—an individual who failed to demonstrate an increase of at least 50% in their score
on the Montgomery-Åsberg Depression Rating Scale (MÅDRS)—when compared to their
baseline score (p. 1137). However, when Murrough et al. compared treatment response with
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treatment type, they found that individuals who received a single administration of ketamine
were more likely to have a response, when compared to individuals who received a treatment of
midazolam (p. 1137). While ketamine’s and midazolam’s AD-like effects decreased over time,
ketamine was more likely to induce observable, positive changes in patients’ moods, as qualified
by the MÅDRS (p. 1137). Murrough et al. also noted that response rates between the ketamine
and midazolam groups did not differ after seven days post-infusion, which indicated that the ADlike effects of ketamine were significantly reduced after seven days. However, ketamine still
resulted in a greater likelihood of ketamine-treated patients having a Clinical Global Impression
score lower than three (p. 1137). The substantiality of ketamine relies on its ability to induce
faster and more robust symptom relief in MDD patients who show inadequate responses to
traditional, clinical ADs.
In order to induce AD-like effects, ketamine increases neuronal activity in the corticomesolimbic pathway. In a study in which 20 MDD patients were administered a single infusion
of ketamine hydrochloride, Cornwell et al. (2012) found that responders, who demonstrated
rapid and extreme reduction in their depressive symptoms, showed an increase in stimulusevoked somatosensory cortex (SS ctx) responses post-infusion of ketamine (p. 559). The results
revealed a positive correlation between levels of plasma norketamine, which is an active
metabolite of ketamine that has a longer half-life than ketamine, and increased cortical
excitability (p. 559). The positive correlation observed in MDD patients supports the idea that
there is a link between ketamine administration and increased cortical activity within the brain.
Currently, there are two proposed hypotheses of how ketamine inhibits NMDARs in
order to lead to increased neuronal activity in the brain. According to Moghaddam et al. (1997),
who studied ketamine’s ability to activate glutamatergic neurotransmission in rats, one
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hypothesis of ketamine’s AD mechanism is that ketamine preferentially inhibits NMDARs that
are located on GABAergic inhibitory interneurons (p. 2923). According to the meta-analysis
conducted by Thompson et al. (2015), the preferential inhibition could be because of differences
in the composition of NMDARs on GABAergic interneurons or because the interneurons
themselves are more depolarized than other types of neurons, thus “relieving ion channel block
by [magnesium ions] and allowing NMDARs to contribute more to [the neurons’] overall
excitation” (p. 288). As a result of inhibiting NMDARs on GABAergic neurons, ketamine is able
to induce a disinhibition or excitation of the neuronal population and potentiate a “surge of
glutamate release” in both the NAc and the PFC (p. 288). However, in a study investigating the
AD action of NMDAR antagonists on mice lacking NMDARs, Pozzi et al. (2014) found that
ketamine is still able to induce AD-like effects in mice that do not have NMDARs in a
subpopulation of GABAergic interneurons. According to Thompson et al. (2015), the study
conducted by Pozzi et al. (2014) suggests that ketamine’s AD-like actions do not rely on
inhibiting NMDARs on GABAergic interneurons in the brain or that another type of interneuron
is crucial in ketamine’s mechanism.
According to Autry et al. (2011), who studied the effects of NMDAR blockade on
behavioral AD responses in clinical trials, the second hypothesis of ketamine’s AD mechanism is
that ketamine inhibits ongoing NMDAR activation (p. 93). Since the ongoing activation of
NMDARs is thought to suppress signaling cascades that promote synaptic transmission in
excitatory neurons, Autry et al. argued that ketamine might promote the production and
expression of proteins like AMPARs, which mediate excitatory synapses, by blocking the
suppression of the excitatory signaling (p. 93).
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Regardless of which of the two hypotheses, both of which focus on excitatory synapses,
is more accurate, ketamine has been proven to induce rapid AD-like effects in depressive-like
rats and depressed humans. However, while ketamine can induce AD-like effects after a single
administration, the drug also causes harmful side effects. Traditional ADs and ketamine both
result in side effects in MDD patients, but research has shown that ketamine often has a higher
abuse liability and can result in psychoactive effects that hinder its clinical viability. Murrough et
al. (2013), who studied ketamine’s and midazolam’s activity in MDD patients, emphasized that
ketamine, which is an NMDAR antagonist, and midazolam, which is an anesthetic
benzodiazepine, both induced adverse effects in treatment-resistant MDD patients (p. 1138). The
fact that patients in the midazolam group demonstrated some side effects indicates that
regardless of the class of drug administered to an MDD patient, some adverse effects like nausea
and headache are likely to occur. However, because of ketamine’s psychoactive effects and
abuse liability, Murrough et al. observed hemodynamic changes and dissociative symptoms in
the ketamine group (p. 1138). Murrough et al.’s findings suggest that ketamine’s psychoactive
effects were induced in the short term.
Due to the risks associated with administering pure ketamine to MDD patients in a
clinical setting, researchers have been studying ketamine-like drugs—like ketamine metabolites
or other compounds that increase synaptic strength—which act via similar mechanisms as
ketamine but lack harmful side effects. The MDD-ketamine trials conducted by Cornwell et al.
(2012) rely on the idea that in order to induce long-lasting changes in the brain’s reward
pathways, the next generation of ketamine-like drugs must increase cortical activity that will, in
turn, allow the brain to form new neural connections to compensate for the changes caused by
chronic stress and MDD. While Gigliucci et al. (2013), in their study with serotonin-depleted

SUBSTANTIALITY OF NEUROPLASTICITY HYPOTHESIS OF MDD

11

rats, did prove that levels of monoamines like serotonin are still vital in ketamine’s ability to
elicit sustained AD activity, Cornwell et al. (2012) demonstrated how rapid and robust
alleviation of depressive symptoms are a result of ketamine’s ability to strengthen glutamatergic
neurotransmission. Ketamine-like drugs that will be used as clinical ADs must act in a similar
manner, by acting on glutamate pathways, to induce AD-like effects within twenty-four hours
after an acute administration.
In order to determine the therapeutic implications of ketamine-like drugs, Fischell et al.
(2015) studied L-655,708 and MRK-016, both of which are ketamine-like drugs, on the behavior
of chronically stressed rats. The research team found that within twenty-four hours of
administration of 0.7 milligrams (mg)/kilogram (kg) of L-655,708—which is an α5-selective
negative allosteric modulator of GABA type A receptors (GABAARs)—the chronic restraint
stress (CRS) rats showed levels of social interaction and sucrose preference that were similar to
their baseline levels (p. 2501). The team also reported that within twenty-four hours of
administration of MRK-016, all CRS rats demonstrated restored sucrose preference and social
interaction levels (p. 2502). Fischell et al. claimed that L-655,708 and MRK-016 both reversed
stress-induced changes in less than twenty-four hours for the Sprague Dawley rats without
producing any detectable side effects (p. 2502).
In a similar study that specifically investigated the AD effects of ketamine metabolites,
Zanos et al. (2016) assessed the effects of (S)-ketamine and (R)-ketamine enantiomers (p. 481).
The researchers noted that, of the broad range of ketamine metabolites, experiments using rats
have shown that (2S,6S;2R,6R)-HNK plays a major role in ketamine’s AD properties (p. 482).
After a series of experiments using a rodent model of depression, Zanos et al. found that (R)ketamine had a greater potency as an AD and that an NMDAR inhibition-independent
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mechanism is likely the explanation for ketamine’s AD properties (p. 482). Zanos et al.
emphasized that (2R,6R)-HNK has “greater antidepressant actions” than (2S,6S)-HNK (p. 483),
which indicates that the former ketamine metabolite demonstrates more clinical viability.
Like Fischell et al. (2015), Zanos et al. (2016) demonstrated how ketamine-like drugs
lack ketamine’s abuse liability but induce AD-like effects. Both teams also concluded that while
ketamine inhibits NMDARs to increase excitatory glutamate synaptic transmission, ketaminelike drugs—including L-655,708, MRK-016, and (2R,6R)-HNK—do not necessarily inhibit
NMDARs and may induce increases in the expression of AMPAR-mediated pathways. Fischell
et al. (2015) reported that decreases in GluA1 protein, which is a subunit of AMPARs,
expression is associated with the neurological and behavioral stress-induced changes seen in
MDD patients—such as “weakened excitatory synaptic transmission at [hippocampus
temporoammonic-CA1 (TA-CA1)] synapses and altered hedonic behavior,” respectively (p.
2505). After analyzing how L-655,708 influenced a rodent model of depression, Fischell et al.
concluded that α5-subunit-selective negative allosteric modulators, like L-655,708, display high
AD efficacy on an electrophysiological, behavioral, and molecular level (p. 2505).
Partial inverse agonists with a low affinity for the benzodiazepine binding site of α5containing GABAARs—including L-655,708—are able to demonstrate potential therapeutic
effects with a minimal likelihood of producing negative adverse effects, such as anxiety.
According to Fischell et al., drugs that specifically target α5-containing GABAARs are able to
alter and strengthen activity within cortico-mesolimbic circuits without adversely affecting other
neurological circuits (p. 2506). The researchers suggested that the ability of “GABAAR negative
allosteric modulators and ketamine to promote activity accounts for their shared” AD effects
because their “activity strengthens excitatory synapses via convergence onto common activity-
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dependent signaling pathways” (p. 2507). Unlike ineffective SSRIs and the easily-abused
ketamine, L-655,708 and MRK-016 induce selective AD effects within twenty-four hours of a
single administration and represent a novel, clinically-viable treatment for MDD.
AMPAR-Mediated AD Pathways
In addition to investigating the behavioral and synaptic changes that ketamine and
ketamine-like drugs induce, researchers have conducted studies to understand the mechanism or
pathway by which the drugs act. In one such study, Cornwell et al. (2012), analyzed the AD-like
effects of ketamine hydrochloride on MDD patients. The team found that NMDAR inhibition has
been proven to increase spontaneous gamma oscillation activity in the SS ctx. According to
Cornwell et al., NMDAR antagonists like ketamine have been known to typically increase
spontaneous γ activity in the SS ctx just after drug administration, when “psychotomimetic
symptoms are most prominent” (p. 559). Cornwell et al.’s study, in particular, showed that in
responders and nonresponders, hours after ketamine infusion, there was no increase in
spontaneous SS ctx γ activity (p. 559). These results indicate that increases in spontaneous SS γ
activity that result from ketamine administration are likely more important to NMDAR
antagonism’s acute, psychoactive effects than they are to the long-term AD effects.
In a similar study that focused on ketamine metabolites instead of pure ketamine, Zanos
et al. (2016) found similar evidence that ketamine metabolites, like (2R,6R)-HNK and (2S,6S)HNK, both activated AMPARs but acted independent of NMDAR inhibition in order to induce
AD effects. While research teams like Thompson et al. (2015)—who conducted the metaanalysis on current depression research—focused on NMDAR antagonists’ ability to quickly
restore stress-induced excitatory synaptic strength, other research teams like Fischell et al.
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(2015)—who studied the AD-like effects of ketamine-like drugs on rats— focused on how drugs
that aim to strengthen weakened AMPAR-mediated signaling are able to exert AD effects.
Fischell et al.’s analyses of brain slices from stressed rats, L-655,708-treated CRS rats,
and vehicle-treated stressed rats confirmed that chronic stress at TA-CA1 synapses suppresses
AMPAR-mediated signaling but does not affect NMDAR-mediated signaling (p. 2504). Fischell
et al. claimed that L-655,708 is able to restore excitatory neurotransmission at the stress-sensitive
TA-CA1 synapses by reversing the impairment of AMPAR-mediated signaling (p. 2504-2505).
These results suggest that ketamine-like drugs, like L-655,708, are able to demonstrate AD
effects via an NMDAR-independent mechanism, which is a similar idea to that proposed by the
aforementioned Zanos et al. (2016).
In a similar study investigating the effects of a ketamine-like drug that acts as an
AMPAR potentiator or positive modulator, Lindholm et al. (2012) discovered that acute LY
451646 treatment neither increased nor decreased mRNA levels of the tropomyosin receptor
kinase B (TrkB) receptor (p. 5). However, Lindholm et al. did note that chronic LY 451646
treatment, with a dose of 0.5 mg/kg, increased TrkB mRNA levels in the DG and the CA4 and
CA3 areas of the hippocampus (p. 5). TrkB is a receptor for BDNF and, in turn, is involved in
neuronal survival and differentiation. The increase of TrkB by LY 451646 indicates that
AMPARs are vital in the brain’s mechanisms to promote neuroplasticity.
As mentioned previously, in a study that was more broadly conducted on the effects of
ketamine hydrochloride on MDD patients, Cornwell et al. (2012) found that NMDAR
antagonists’ ability to increase spontaneous SS ctx γ activity was limited to a short period of time
directly after the drug was taken (p. 559). Cornwell et al. suggested that since increases in
spontaneous SS ctx γ were not seen in responders and nonresponders, “the immediate effects of
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NMDAR antagonism might not be sufficient to elicit rapid clinical improvements” (p. 559). The
researchers claimed that elevated cortical excitability six to seven hours post-infusion was not
caused by ketamine-induced disinhibition of glutamatergic neurons or differences in extracellular
glutamate levels between responders and nonresponders (p. 559-560). While “ketamine-induced
disinhibition and increased glutamatergic activity are too transient” to directly ameliorate
depressive symptoms, both processes could “trigger critical plastic changes at excitatory
synapses that mediate” the increases in cortical excitability seen in responders (p. 560).
According to the team, due to the fact that AMPAR-mediated neurotransmission plays a role in
recruiting GABAergic interneurons, increased stimulus-evoked γ-band responses in SS ctx might
confirm “enhanced AMPAR-mediated glutamatergic drive of interneuronal networks” (p. 560).
The study by Cornwell et al. raises the notion that if NMDAR antagonism is not a
starting point for therapeutically altering cortical circuitry to benefit MDD patients, newly
developed ADs could focus on directly triggering synaptic potentiation rather than indirectly via
NMDAR antagonists. Thus, Cornwell et al.’s findings suggest that ketamine’s AD-like effects
rely on “enhanced non-NMDAR-mediated glutamatergic neurotransmission through synaptic
potentiation” (p. 560). However, further research is needed to determine whether increased
cortical excitability is associated with response to MDD therapies in general or is specific to
glutamatergic drugs and to investigate the roles that AMPARs and NMDARs play in plastic
changes within the human brain.
Overlap Between the Monoamine and Neuroplasticity Hypotheses of MDD
As researchers have investigated the mechanism by which ketamine and ketamine-like
drugs potentiate excitatory synaptic transmission, some teams have also evaluated the role that
monoamine neurotransmitters play in the drugs’ AD-like activity. In such studies, researchers
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investigated how biogenic-amine pathways intersect with glutamatergic or AMPAR-mediated
systems that increase neuroplasticity.
In one such study that evaluated the interaction of AMPAR potentiators and traditional
ADs in mice, Li et al. (2003) claimed that while LY 392098 increased the potency of the
tricyclic AD imipramine, the AMPAR potentiator did not alter concentrations of imipramine in
the brain (p. 425). While SSRIs like fluoxetine rely on the increased synaptic availability of a
biogenic amine like serotonin, Li et al.’s results suggest that LY 392098’s ability to induce
increases in the potencies of conventional ADs in the forced swim test (FST) is a result of
downstream effects that are produced by increased synaptic availability of biogenic amines
combining with pathways that have been stimulated by the activation of AMPARs (p. 427). The
team’s findings suggest that the neuroplasticity hypotheses of MDD and the monoamine
hypotheses of MDD converge. Li et al. argued that, in the case of LY 392098 and ketamine, each
drug relies on biogenic amines like serotonin in order to maximize their AD properties.
Like Li et al., Gigliucci et al. (2013)—in their study on serotonin-depleted rats—found
that while ketamine did not alter serotonin levels in the frontal cortex, serotonin depletion
“attenuated the AD-like effect of ketamine” (p. 161). In the study, there was an increase in
immobility for the rats that were serotonin-depleted, stress-exposed, and ketamine-treated when
compared to the rats that were serotonin-depleted, non-stressed, and ketamine-treated (p. 161).
Gigliucci et al. suggested that the timing of ketamine administration and the dose administered
can either enhance or hinder the drug’s AD effects (p. 163). According to the team, ketamine
promotes neuronal changes that enhance the efficacy of central serotonin in synapses; however,
further research using the FST must be conducted to understand the role of serotonin in relation
to emerging views of depression and ADs (p. 165).
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In a similar investigation of the AD-like effects of ketamine and fluoxetine on depressive
mice, Pham et al. (2017) found that both ketamine and fluoxetine increase extracellular serotonin
levels in the medial PFC (p. 202). The team concluded that in a rodent model of depression,
serotonin plays a role in ketamine’s behavioral activity, the AD-like activity of ketamine recruits
the neural circuit involving the PFC and the brainstem dorsal raphe nucleus (DRN), and
ketamine’s ability to act like an AD requires the activation of AMPARs on the DRN (p. 204).
According to Pham et al., the AD-like activity of ketamine, rather than that of fluoxetine, relies
on interactions between serotonergic and glutamatergic systems within the medial PFC (p. 208).
These results, like those of Gigliucci et al. (2013), indicate that ketamine’s ability to induce rapid
AD-like activity relies not only on glutamatergic systems that regulate neuroplasticity but also on
serotonergic systems that regulate the levels of monoamine neurotransmitters.
Based on the research conducted by Li et al. (2003), Gigliucci et al. (2013), and Pham et
al. (2017), while the long-standing monoamine theory of MDD is often discussed in a separate
context from the neuroplasticity hypothesis of MDD, both have substantial overlap. The
monoamine theory focuses on how increases in monoaminergic neurotransmitter levels
positively impact mood and behavior, while the neuroplasticity hypothesis draws attention to the
fact that strengthening glutamatergic synapses can support the brain’s reward pathway as a
whole. Despite their different focuses, the monoamine theory and the neuroplasticity theory
overlap in their discussion of the brain’s complex network of communication; levels of
monoamines like serotonin and neuronal pathways that increase synaptic strength are vital in
ketamine’s and ketamine-like drugs’ ability to elicit sustained AD activity.

Synergism Between AMPAR Potentiators and Biogenic-Amine-Based ADs
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In addition to supporting the idea regarding an overlap between the monoamine
hypothesis of MDD and the neuroplasticity hypothesis of MDD, preliminary research indicates
that drugs based on both hypotheses may interact to produce AD effects that are faster and more
robust than either class of drugs alone. Studies demonstrate a synergism between ketamine-like
drugs—based on the neuroplasticity hypothesis—that activate AMPARs to promote AD-effects
in the cortico-mesolimbic reward pathway and traditional ADs—based on the monoamine
hypothesis—that alter biogenic amine levels in synaptic clefts. In one such study that
investigated the interaction of AMPAR potentiators and traditional ADs, Li et al. (2003)
observed that LY 392098 reduced the minimal effective dose of seven traditional ADs, including
rolipram, citalopram, duloxetine, imipramine, nisoxetine, tranylcypromine, and fluoxetine (p.
423). Li et al. also observed that LY 392098 increased the relative potency of all seven of the
aforementioned ADs, excluding tranylcypromine (p. 423). Li et al. concluded that the synergism
between AMPAR potentiators like LY 392098 and conventional ADs like SSRIs suggests that in
order to increase the efficacy of commonly prescribed AD medications, like fluoxetine or
Prozac, combination therapies that combine the original AD with an AMPAR potentiator would
be more successful than administering the original ADs alone.
Mackowiak et al. (2002)—who also studied the activity of an AMPAR-potentiating
ketamine-like drug but used a rodent model of depression—claimed that one mg/kg of LY
404187, which is a racemic AMPAR potentiator, increased the number of BDNF-positive cells
in the DG when administered chronically, over the course of seven days (p. 4). Li et al. (2003)
claimed that AMPAR potentiators and conventional ADs like fluoxetine demonstrate a
synergism when administered together. One probable explanation for the synergism between
novel AMPAR potentiators and traditional ADs is increased BDNF expression, which, as shown
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by Mackowiak et al. (2002), can result from AMPAR potentiators acting on the DG and
hippocampus.

Conclusion
The synergism between AMPAR potentiators like LY 392098 and conventional ADs like
SSRIs suggests that in order to increase the efficacy of commonly prescribed AD medications for
MDD patients, combination therapies that combine traditional ADs with an AMPAR potentiator
would be more successful than administering the original ADs alone. While ketamine is often
classified as an NMDAR antagonist or inhibitor, the drug can be described more accurately as an
AMPAR potentiator. As seen in the study conducted by Zanos et. al (2016), (2R,6R)-HNK, a
ketamine metabolite that lacks harmful side effects, induces AD effects via sustained activation
of AMPARs; such research further suggests that ketamine’s and ketamine-like drugs’ AD effects
rely on their ability to interact with AMPARs. After conducting a study on serotonin-depleted
rats, Gigliucci et al. (2013) also noted that ketamine’s AD effects rely on AMPAR activation.
Fischell et al. (2015), who studied the activity of ketamine-like drugs on rats, reported that L655,708, an α5-selective negative allosteric modulator of GABAARs, is able to act as a ketaminelike AMPAR potentiator that reverses stress-induced changes in hedonic behavior.
Since ketamine can be classified as an AMPAR potentiator, it can be considered as a
compound that can increase the potency of conventional ADs and a compound whose potency
can be increased by conventional ADs. While studies have shown that a single administration of
ketamine or ketamine-like drugs—like the NMDAR antagonist esketamine that has been recently
marketed as a novel AD—has had longer-lasting AD effects compared to chronic administration
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of traditional ADs, it is possible that the AD effects of ketamine-like drugs, specifically
AMPAR-potentiating drugs, can be increased further by combining the drugs with a traditional
AD. Such a combination would extend the relief MDD patients receive from a single dose of
their AD medication.
Future studies investigating the AD effects of a dual-drug treatment with an AMPARpotentiating ketamine-like drug and a biogenic-amine-based AD must be conducted on rats and
MDD patients. As seen by Duric et al. (2012), who studied the expression of synapse-related
genes in rats’ and MDD patients’ hippocampi, chronic stress does not induce the same alterations
in serotonin receptor expression in rats as in humans. In the study, Duric et al. found that chronic
unpredictable stress (CUS) and AD treatment did not alter the expression of HTR genes, which
are involved in coding for serotonin receptors, in the same way that MDD alters the expression
of synapse-related genes in humans (p. 78). The research team acknowledged the fact that MDD
manifests uniquely in different species. Even though animal models of depression like CUS
rodents are similar to MDD in humans, chronic stress does not result in the same exact changes
in animals as it does in humans.
In order to develop novel AD treatments that are more robust than currently prescribed
AD drugs, future studies must not only investigate how ketamine-like drugs and traditional ADs
interact within the human body but also what doses are needed for acute administrations of the
dual-drug treatment. Longitudinal studies are needed to understand both the short-term and longterm effects that the dual-drug treatments will have on MDD patients’ mood and hedonic
motivation. The dual-drug treatments, which would maximize the synergism between longstanding and novel ADs, may offer a new therapy method that would attenuate the severe
depressive symptoms faced by a large population of treatment-resistant MDD patients.
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